Protalix BioTherapeutics Inc. (NYSE:PLX) has earned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy recommendation.
Brokerages have set a one year consensus target price of $2.15 for the company and are expecting that the company will post ($0.10) earnings per share for the current quarter, according to Zacks. Zacks has also given Protalix BioTherapeutics an industry rank of 105 out of 265 based on the ratings given to its competitors.
Several analysts recently commented on PLX shares. Jefferies Group cut their target price on shares of Protalix BioTherapeutics from $1.75 to $0.80 and set a “buy” rating for the company in a research note on Tuesday, September 6th. Zacks Investment Research downgraded shares of Protalix BioTherapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 24th. Finally, Rodman & Renshaw restated a “buy” rating on shares of Protalix BioTherapeutics in a research report on Monday, July 11th.
Protalix BioTherapeutics (NYSE:PLX) opened at 0.485 on Friday. Protalix BioTherapeutics has a 12-month low of $0.48 and a 12-month high of $1.25. The company’s 50 day moving average is $0.58 and its 200 day moving average is $0.70. The firm has a market cap of $48.38 million and a price-to-earnings ratio of 0.958.
Protalix BioTherapeutics (NYSE:PLX) last released its earnings results on Monday, August 8th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.03. The company had revenue of $1.77 million for the quarter, compared to analyst estimates of $1.34 million. During the same period in the previous year, the company posted ($0.05) earnings per share. On average, equities analysts anticipate that Protalix BioTherapeutics will post ($0.41) earnings per share for the current year.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Protalix BioTherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.